0001214659-22-002681.txt : 20220214 0001214659-22-002681.hdr.sgml : 20220214 20220214165129 ACCESSION NUMBER: 0001214659-22-002681 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220211 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FUCHS HENRY J CENTRAL INDEX KEY: 0001197355 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 22633843 MAIL ADDRESS: STREET 1: C/O BIOMARIN PHARMACEUTICAL INC. STREET 2: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3545 CRAY COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 3545 CRAY COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-55390.xml PRIMARY DOCUMENT X0306 4 2022-02-11 0001576263 Mirati Therapeutics, Inc. MRTX 0001197355 FUCHS HENRY J C/O MIRATI THERAPEUTICS INC. 3545 CRAY COURT SAN DIEGO CA 92121 true false false false Common Stock 2022-02-11 4 M false 6000 20.54 A 12021 D Common Stock 2022-02-11 4 M false 5000 20.54 A 17021 D Common Stock 2022-02-11 4 S false 2090 104.7646 D 14931 D Common Stock 2022-02-11 4 S false 8700 105.7963 D 6231 D Common Stock 2022-02-11 4 S false 210 106.3407 D 6021 D Non Qualified Stock Option (right to buy) 20.54 2022-02-11 4 M false 6000 0 D 2017-09-09 2024-09-08 Common Stock 6000 0 D Non Qualified Stock Option (right to buy) 20.54 2022-02-11 4 M false 5000 0 D 2014-09-09 2024-09-08 Common Stock 5000 0 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. This transaction was executed in multiple trades at prices ranging from $104.23 to $105.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $105.28 to $106.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $106.33 to $106.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Vickie Reed, Attorney-in-Fact 2022-02-14